Jonathan Alspaugh's Insider Trades & SAST Disclosures
Jonathan Alspaugh's most recent trade in Aeglea BioTherapeutics Inc was a trade of 19,787,969 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on June 22, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jonathan Alspaugh.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 19,787,969 | 19,787,969 | - | - | Employee Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 640,000 | 640,000 | - | - | Employee Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.08 per share. | 11 Mar 2022 | 75,000 | 165,372 (0%) | 0% | 2.1 | 156,000 | Common Stock |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 170,000 | 170,000 | - | - | Employee Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.72 per share. | 09 Dec 2021 | 50,000 | 90,372 (0%) | 0% | 3.7 | 186,000 | Common Stock |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.50 per share. | 16 Aug 2021 | 23,392 | 33,172 (0%) | 0% | 6.5 | 151,985 | Common Stock |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.37 per share. | 16 Aug 2021 | 9,780 | 9,780 (0%) | 0% | 6.4 | 62,275 | Common Stock |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.72 per share. | 16 Aug 2021 | 7,200 | 40,372 (0%) | 0% | 6.7 | 48,400 | Common Stock |
| Aeglea BioTherapeutics Inc | Jonathan Alspaugh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges